Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5614857 | Journal of Cardiology | 2016 | 7 Pages |
Abstract
The protein C level/activity was significantly and consistently higher in the rivaroxaban-treated patients than in the warfarin-treated patients throughout the day, which was in contrast to the findings for other coagulation assays. These findings may partly explain the specific persistent anticoagulant effects of rivaroxaban even during the trough phase of the plasma concentration.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Yuka MD, Masahiro MD, PhD, Bo PhD, Shunichiro MD, Yoshihisa MD, PhD, Joji MD, PhD, Satoshi MD, PhD, FJCC, Tomoo MD, PhD, Naomichi MD, PhD, Akira MD, PhD, Keijiro MD, PhD, FJCC,